Signpath Pharma Inc.

22 patents currently held · Updated Nov 14, 2026

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Ending by 2030

Mar 2028

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Jan 16 to 23, 2027 · next Jan 16
1 fee due Mar 5, 2027
The maintenance fee for Cardiopathy-Reducing Phosphodiester Lipids (US 11,746,119) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
1 fee due Apr 22, 2027
The maintenance fee for Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies (US 10,449,193) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
3 fees due May 7 to 26, 2027 · next May 7
1 fee due Jul 14, 2027
The maintenance fee for Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel (US 10,532,045) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
1 fee due Oct 14, 2027
The maintenance fee for Liposomal Mitigation of Drug-Induced Long QT Syndrome and Potassium Delayed-Rectifier Current (US 10,617,639) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 8,784,881	Liposomal Curcumin for Treatment of Diseases In force Term ends Mar 10, 2028 · High confidence	In force	Term ends Mar 10, 2028	High confidence
US 9,393,198	Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders In force Ends no later than Mar 21, 2031 · From the USPTO record	In force	Ends no later than Mar 21, 2031	From the USPTO record
US 8,747,890	Intravenous infusion of curcumin and a calcium channel blocker In force Term ends Nov 1, 2031 · From the USPTO record	In force	Term ends Nov 1, 2031	From the USPTO record
US 8,753,674	Liposomal Mitigation of Drug-Induced Long QT Syndrome and Potassium Delayed-Rectifier Current In force Term ends Jun 3, 2032 · High confidence	In force	Term ends Jun 3, 2032	High confidence
US 9,682,041	Liposomal Mitigation of Drug-Induced Long QT Syndrome and Potassium Delayed-Rectifier Current In force Term ends Jun 3, 2032 · High confidence	In force	Term ends Jun 3, 2032	High confidence
US 10,117,881	Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies In force Ends no later than Jun 3, 2032 · From the USPTO record	In force	Ends no later than Jun 3, 2032	From the USPTO record
US 10,238,602	Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies In force Ends no later than Jun 3, 2032 · From the USPTO record	In force	Ends no later than Jun 3, 2032	From the USPTO record
US 10,349,884	Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel In force Ends no later than Jun 3, 2032 · From the USPTO record	In force	Ends no later than Jun 3, 2032	From the USPTO record
US 10,357,458	Liposomal Mitigation of Drug-Induced Long QT Syndrome and Potassium Delayed-Rectifier Current In force Term ends Jun 3, 2032 · High confidence	In force	Term ends Jun 3, 2032	High confidence
US 10,449,193	Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies In force Ends no later than Jun 3, 2032 · From the USPTO record	In force	Ends no later than Jun 3, 2032	From the USPTO record

10 of 22 patents shown.

Pro members see all 22.

Pro members: see all 22 patents

Also on record, not counted in the 22: 1 patent in force now held by others · 1 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 1 abandoned · 14 no status recorded

List them